← Leaderboards
Elisha Wachman
Boston Medical Center
$6,271,367
Attributed
$6,876,944
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2018–25$5M$3.8M$2.5M$1.3M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,876,944 · 3
By mechanism
R01$5,968,578 · 2
K12$908,366 · 1
Top collaborators
- Emelia J. Benjamin1 shared
- Joyce Y Wong1 shared
Most similar at Boston Medical Center
Same institution · by research overlap
- Jane M Liebschutz$5,811,997
- Judith Tsui$9,934,962
- Tae Woo Park$926,892
- Karsten Lunze$5,048,816
- Alyssa Tilhou$563,555
Others in their field
Other Emerging Leaders on “Exposure To”
- Chanza Baytop · Westat, Inc.$271,217,917
- Yunda Huang · Fred Hutchinson Cancer Center$65,418,952
- Prasant Mohapatra · University Of California At Davis$51,108,355
- Ellen Gould Chadwick · Harvard University D/B/A Harvard School Of Public Health$25,473,113
- Leonard Freedman · Leidos Biomedical Research, Inc.$20,851,347
- Kristin Aillon · Midwest Research Institute$18,958,174
Research focus
Exposure ToMedical CenterInfantSuccessBostonModificationOpioidNeurodevelopmentPlasmaPregnancy OutcomeUniversitiesPregnancyFutureFetalUmbilical Cord BloodGrowthDoseDna MethylationDrug KineticsAnimalsAddictionComparativeHuman DataHuman Milk
Grant awards (8)
Boston University BIRCWH$908,366
K12 · FY2025 · AR
Association of maternal, fetal and placental biomarkers with neonatal neuroimaging and development following in-utero opioid exposure$2,573,346
R01 · FY2023 · HD · contact PI
Safety, pharmacokinetics and efficacy of extended-release naltrexone in pregnant women with opioid use disorder$613,662
R01 · FY2022 · HD · contact PI
Safety, Efficacy, Pharmacokinetics, and Pharmacogenomics of Extended-Release Naltrexone in Pregnant Women - Administrative Supplement$120,476
R01 · FY2022 · HD · contact PI
Safety, pharmacokinetics and efficacy of extended-release naltrexone in pregnant women with opioid use disorder$624,404
R01 · FY2021 · HD · contact PI
Safety, pharmacokinetics and efficacy of extended-release naltrexone in pregnant women with opioid use disorder$646,039
R01 · FY2020 · HD · contact PI
Safety, pharmacokinetics and efficacy of extended-release naltrexone in pregnant women with opioid use disorder$667,852
R01 · FY2019 · HD · contact PI
Safety, pharmacokinetics and efficacy of extended-release naltrexone in pregnant women with opioid use disorder$722,799
R01 · FY2018 · HD · contact PI